Registration is open now for five new webinars in May. These educational opportunities developed by the SSO Education Council in partnership with SSO’s Disease Site Work Groups cover various disease sites. ExpertED@SSO webinars are one of the many benefits that are included in your SSO membership. Register now.
Should a Patient with a 2 cm HER2+/TNBC Clinically Node Negative Receive Neoadjuvant Therapy? |
May 9, 2019 | 2 pm CT
Faculty: Julie Margenthaler, MD and Sarah McLaughlin, MD
Based on the SSO 2019 Great Debate, this webinar will present data and compare and contrast the benefits and limitations of upfront surgery and neoadjuvant therapy for resectable HER2+/TNBC.
You may find this activity in the Breast Disease section in the ExpertED@SSO catalog.
This activity is partially supported by an independent educational grant from Genentech.
Young Adult Onset Colorectal Cancer: What is going on? | May 15, 2019 | 3 pm CT
Faculty: J. Joshua Smith, MD, PhD, Y. Nancy You, MD, MHSc, and Heather Yeo, MD, MHS.
Young-onset colorectal cancer is distinct in many ways. Location of the tumor varies substantially with age and cancers are also histologically more aggressive. This webinar will review practice changing papers and national screening guidelines and age-related differences in colorectal cancer that have implications for diagnosis and treatment.
You may find this activity in the Colorectal Disease section in the ExpertED@SSO catalog.
Breast Cancer: Genetic Testing and Management | May 22, 2019 | 3 pm CT
Faculty: Marissa Howard-McNatt, MD, David Euhus, MD, Thuy Vu, MS, CGC, Brittany Puster
In this webinar, based on the SSO 2019 session, participants will learn about newly identified hereditary genetic mutations that put a patient at a higher risk for breast cancer. The content covered will include what genetic tests to order along with the appropriate treatment options for patients with certain genetic mutations.
You may find this activity in the Breast Disease section in the ExpertED@SSO catalog.
Multi-Modality Management of Stage IV Melanoma in the Era of Immunotherapy |May 29, 2019 | 5 pm CT
Faculty: Omid Hamid, MD, Genevieve Boland, MD, PhD, Mark Faries, MD and Charlotte Ariyan, MD
Learn about the mechanisms of action and toxicities of novel immunotherapeutic agents for metastatic melanoma and how to best integrate these agents with surgical options. Four specific topics will be covered including: systemic therapy, immune adjuvants for Stage IV melanoma, management of oligometastatic disease and surgical outcomes in melanoma in combination with immunotherapy.
You may find this activity in the Melanoma Disease section in the ExpertED@SSO catalog.
This activity is partially supported by independent educational grants from Amgen, Bristol Myers Squibb and Merck.